JP2005538065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538065A5 JP2005538065A5 JP2004513473A JP2004513473A JP2005538065A5 JP 2005538065 A5 JP2005538065 A5 JP 2005538065A5 JP 2004513473 A JP2004513473 A JP 2004513473A JP 2004513473 A JP2004513473 A JP 2004513473A JP 2005538065 A5 JP2005538065 A5 JP 2005538065A5
- Authority
- JP
- Japan
- Prior art keywords
- serotonin
- antagonist
- compound
- fluphenazine
- brain barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38957702P | 2002-06-17 | 2002-06-17 | |
| US41483102P | 2002-09-27 | 2002-09-27 | |
| PCT/US2003/019595 WO2003106660A2 (en) | 2002-06-17 | 2003-06-17 | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538065A JP2005538065A (ja) | 2005-12-15 |
| JP2005538065A5 true JP2005538065A5 (https=) | 2006-07-27 |
Family
ID=29740159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004513473A Pending JP2005538065A (ja) | 2002-06-17 | 2003-06-17 | セロトニンファミリーの受容体および血液脳関門に関する免疫調節および細胞過程への影響 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20060183757A1 (https=) |
| EP (1) | EP1534256A4 (https=) |
| JP (1) | JP2005538065A (https=) |
| CN (2) | CN102018715A (https=) |
| AU (1) | AU2003276445A1 (https=) |
| CA (1) | CA2488708A1 (https=) |
| WO (1) | WO2003106660A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003996A1 (en) * | 2002-06-17 | 2006-01-05 | Stephen Roth | Intralesional treatment of psoriasis |
| KR100675432B1 (ko) * | 2004-10-04 | 2007-01-29 | 캄텍주식회사 | 차량 배기 가스 재순환 밸브의 개폐 구조 |
| US20060287301A1 (en) * | 2005-06-17 | 2006-12-21 | Mcnair Douglas | Novel formulations for phenothiazines, including fluphenazine and its derivatives |
| CA2662215A1 (en) | 2006-09-01 | 2008-03-06 | Immune Control, Inc. | Novel compositions and methods for treatment of diseases related to activated lymphocytes |
| JP2008156297A (ja) * | 2006-12-25 | 2008-07-10 | Hokkaido Univ | セロトニン２ｂおよび／または２ｃ受容体拮抗剤 |
| GB0701170D0 (en) * | 2007-01-22 | 2007-02-28 | Imp Innovations Ltd | Compositions and uses thereof |
| CA2683316A1 (en) | 2007-04-13 | 2009-02-19 | Southern Research Institute | Anti-angiogenic agents and methods of use |
| WO2009108635A2 (en) * | 2008-02-29 | 2009-09-03 | Immune Control, Inc. | Novel compositions and methods for treatment of diseases related to activated lymphocytes |
| DK3106166T3 (da) | 2008-02-29 | 2021-01-11 | Vm Therapeutics Llc | Forbindelser til behandling af smertesyndrom og andre lidelser |
| AU2009231892A1 (en) * | 2008-03-31 | 2009-10-08 | The Trustees Of Columbia University In The City Of New York | Methods of diagnosing, preventing and treating bone mass diseases |
| WO2010124100A1 (en) * | 2009-04-22 | 2010-10-28 | Immune Control, Inc. | Novel selective 5-ht4 receptor antagonists |
| WO2011053977A1 (en) | 2009-11-02 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
| CA2816551A1 (en) * | 2010-11-03 | 2012-05-10 | Mcmaster University | Method of treating mucosal inflammation |
| TR201903280T4 (tr) * | 2011-08-02 | 2019-04-22 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Malt1 proteazının fenotiazin türevleri ile selektif inhibisyonu. |
| WO2019175332A1 (en) * | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN119789869A (zh) * | 2022-06-30 | 2025-04-08 | 嘉惟思远制药有限公司 | 医药组合物 |
| CN116731165B (zh) * | 2023-03-23 | 2024-08-13 | 北京巴瑞医疗器械有限公司 | 一种抗血清素抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
| US5104858A (en) * | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
| EP0489108B1 (en) * | 1989-08-21 | 1996-03-13 | Beth Israel Hospital Association | Use of spiperone derivatives for immunosuppression |
| US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| WO1992016226A1 (en) * | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
| US5658955A (en) * | 1994-11-01 | 1997-08-19 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of immune disorders |
| WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
| IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
| WO2002057244A1 (en) * | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| AU2002305123B2 (en) * | 2001-03-30 | 2006-10-05 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
| US20040072824A1 (en) * | 2001-06-01 | 2004-04-15 | Adam Telerman | Methods and compositions for the treatment of cancer |
| DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
-
2003
- 2003-06-17 CA CA002488708A patent/CA2488708A1/en not_active Abandoned
- 2003-06-17 AU AU2003276445A patent/AU2003276445A1/en not_active Abandoned
- 2003-06-17 CN CN2010101667387A patent/CN102018715A/zh active Pending
- 2003-06-17 CN CNA038195291A patent/CN1674879A/zh active Pending
- 2003-06-17 EP EP03742117A patent/EP1534256A4/en not_active Withdrawn
- 2003-06-17 JP JP2004513473A patent/JP2005538065A/ja active Pending
- 2003-06-17 WO PCT/US2003/019595 patent/WO2003106660A2/en not_active Ceased
-
2004
- 2004-12-16 US US11/013,969 patent/US20060183757A1/en not_active Abandoned
-
2005
- 2005-12-02 US US11/293,733 patent/US20060135415A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538065A5 (https=) | ||
| Watad et al. | The early phases of ankylosing spondylitis: emerging insights from clinical and basic science | |
| Salazar et al. | Alzheimer's disease risk factor Pyk2 mediates amyloid-β-induced synaptic dysfunction and loss | |
| Tillage et al. | Elimination of galanin synthesis in noradrenergic neurons reduces galanin in select brain areas and promotes active coping behaviors | |
| Gallagher et al. | Relationship of age-related decline across several behavioral domains | |
| Pelleymounter et al. | Hippocampal 3H-CPP binding and spatial learning deficits in aged rats | |
| Yang et al. | Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses | |
| Yoneda et al. | Peripubertal exposure to the neonicotinoid pesticide dinotefuran affects dopaminergic neurons and causes hyperactivity in male mice | |
| Le et al. | Prion neurotoxicity | |
| Dahdah et al. | Germinal center B cells are essential for collagen‐induced arthritis | |
| Gherzi et al. | Reevaluation of the evidence that an antibody to the insulin receptor is insulinmimetic without activating the protein tyrosine kinase activity of the receptor. | |
| Tong et al. | Expression of c-kit messenger ribonucleic acid and c-kit protein in sigmoid colon of patients with slow transit constipation | |
| DE3650647T2 (de) | Arzneimittel zur Behandlung von Anxietas | |
| Rana et al. | Constitutive vagus nerve activation modulates immune suppression in sepsis survivors | |
| JP2014210824A (ja) | 胃腸疾患の治療方法および組成物 | |
| Ghidoni et al. | Circulating progranulin as a biomarker for neurodegenerative diseases | |
| Otto et al. | The α7 nicotinic acetylcholine receptors regulate hippocampal adult-neurogenesis in a sexually dimorphic fashion | |
| Lindblad et al. | The N-methyl-d-aspartic acid receptor antagonist memantine ameliorates and delays the development of arthritis by enhancing regulatory T cells | |
| Tay et al. | Juvenile spondyloarthritis: what more do we know about HLA-B27, enthesitis, and new bone formation? | |
| Hirata et al. | Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome | |
| Rosendahl et al. | Adaptive immunity and IL‐17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice | |
| Erdogan et al. | Neuronal–immune axis alters pain and sensory afferent damage during dental pulp injury | |
| Van der Zee et al. | Delayed peripheral nerve regeneration and central nervous system collateral sprouting in leucocyte common antigen‐related protein tyrosine phosphatase‐deficient mice | |
| Lauten et al. | TH17/Treg lymphocyte balance is regulated by beta adrenergic and cAMP signaling | |
| Friedman et al. | Cleft palate, retrognathia and congenital heart disease in velo-cardio-facial syndrome: a phenotype correlation study |